101 related articles for article (PubMed ID: 22868228)
1. N-1-Alkyl-2-oxo-2-aryl amides as novel antagonists of the TRPA1 receptor.
Vallin KS; Sterky KJ; Nyman E; Bernström J; From R; Linde C; Minidis AB; Nolting A; Närhi K; Santangelo EM; Sehgelmeble FW; Sohn D; Strindlund J; Weigelt D
Bioorg Med Chem Lett; 2012 Sep; 22(17):5485-92. PubMed ID: 22868228
[TBL] [Abstract][Full Text] [Related]
2. Tetrahydro-β-carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channels.
Ortar G; De Petrocellis L; Moriello AS; Allarà M; Morera E; Nalli M; Di Marzo V
Bioorg Med Chem Lett; 2013 Jan; 23(1):138-42. PubMed ID: 23206861
[TBL] [Abstract][Full Text] [Related]
3. Sustained TRPA1 activation in vivo.
Koivisto A
Acta Physiol (Oxf); 2012 Feb; 204(2):248-54. PubMed ID: 21518269
[TBL] [Abstract][Full Text] [Related]
4. Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597).
Niforatos W; Zhang XF; Lake MR; Walter KA; Neelands T; Holzman TF; Scott VE; Faltynek CR; Moreland RB; Chen J
Mol Pharmacol; 2007 May; 71(5):1209-16. PubMed ID: 17314320
[TBL] [Abstract][Full Text] [Related]
5. Oxime derivatives related to AP18: Agonists and antagonists of the TRPA1 receptor.
Defalco J; Steiger D; Gustafson A; Emerling DE; Kelly MG; Duncton MA
Bioorg Med Chem Lett; 2010 Jan; 20(1):276-9. PubMed ID: 19945872
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
Morera E; De Petrocellis L; Morera L; Moriello AS; Ligresti A; Nalli M; Woodward DF; Di Marzo V; Ortar G
Bioorg Med Chem Lett; 2009 Dec; 19(23):6806-9. PubMed ID: 19875281
[TBL] [Abstract][Full Text] [Related]
7. Tricyclic 3,4-dihydropyrimidine-2-thione derivatives as potent TRPA1 antagonists.
Gijsen HJ; Berthelot D; De Cleyn MA; Geuens I; Brône B; Mercken M
Bioorg Med Chem Lett; 2012 Jan; 22(2):797-800. PubMed ID: 22222037
[TBL] [Abstract][Full Text] [Related]
8. Development of novel azabenzofuran TRPA1 antagonists as in vivo tools.
Copeland KW; Boezio AA; Cheung E; Lee J; Olivieri P; Schenkel LB; Wan Q; Wang W; Wells MC; Youngblood B; Gavva NR; Lehto SG; Geuns-Meyer S
Bioorg Med Chem Lett; 2014 Aug; 24(15):3464-8. PubMed ID: 24953819
[TBL] [Abstract][Full Text] [Related]
9. Differentiation dependent expression of TRPA1 and TRPM8 channels in IMR-32 human neuroblastoma cells.
Louhivuori LM; Bart G; Larsson KP; Louhivuori V; Näsman J; Nordström T; Koivisto AP; Akerman KE
J Cell Physiol; 2009 Oct; 221(1):67-74. PubMed ID: 19507192
[TBL] [Abstract][Full Text] [Related]
10. Activation of TRPA1 by farnesyl thiosalicylic acid.
Maher M; Ao H; Banke T; Nasser N; Wu NT; Breitenbucher JG; Chaplan SR; Wickenden AD
Mol Pharmacol; 2008 Apr; 73(4):1225-34. PubMed ID: 18171730
[TBL] [Abstract][Full Text] [Related]
11. Utility of large-scale transiently transfected cells for cell-based high-throughput screens to identify transient receptor potential channel A1 (TRPA1) antagonists.
Chen J; Lake MR; Sabet RS; Niforatos W; Pratt SD; Cassar SC; Xu J; Gopalakrishnan S; Pereda-Lopez A; Gopalakrishnan M; Holzman TF; Moreland RB; Walter KA; Faltynek CR; Warrior U; Scott VE
J Biomol Screen; 2007 Feb; 12(1):61-9. PubMed ID: 17099245
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the biology and medicinal chemistry of TRPA1.
Rech JC; Eckert WA; Maher MP; Banke T; Bhattacharya A; Wickenden AD
Future Med Chem; 2010 May; 2(5):843-58. PubMed ID: 21426205
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a series of aryl-N-(3-(alkylamino)-5-(trifluoromethyl)phenyl)benzamides as TRPA1 antagonists.
Laliberté S; Vallée F; Fournier PA; Bedard L; Labrecque J; Albert JS
Bioorg Med Chem Lett; 2014 Jul; 24(14):3204-6. PubMed ID: 24880903
[TBL] [Abstract][Full Text] [Related]
14. Enhanced activation of the transient receptor potential channel TRPA1 by ajoene, an allicin derivative.
Yassaka RT; Inagaki H; Fujino T; Nakatani K; Kubo T
Neurosci Res; 2010 Jan; 66(1):99-105. PubMed ID: 19808063
[TBL] [Abstract][Full Text] [Related]
15. NPPB structure-specifically activates TRPA1 channels.
Liu K; Samuel M; Ho M; Harrison RK; Paslay JW
Biochem Pharmacol; 2010 Jul; 80(1):113-21. PubMed ID: 20226176
[TBL] [Abstract][Full Text] [Related]
16. 2-Amino-4-arylthiazole compounds as TRPA1 antagonists (WO 2012085662): a patent evaluation.
De Petrocellis L; Schiano Moriello A
Expert Opin Ther Pat; 2013 Jan; 23(1):119-47. PubMed ID: 23126422
[TBL] [Abstract][Full Text] [Related]
17. The dilated TRPA1 channel pore state is blocked by amiloride and analogues.
Banke TG
Brain Res; 2011 Mar; 1381():21-30. PubMed ID: 21241666
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of resveratrol derivatives as new analgesic drugs through desensitization of the TRPA1 receptor.
Nakao S; Mabuchi M; Wang S; Kogure Y; Shimizu T; Noguchi K; Tanaka A; Dai Y
Bioorg Med Chem Lett; 2017 Jul; 27(14):3167-3172. PubMed ID: 28576617
[TBL] [Abstract][Full Text] [Related]
19. Analogues of morphanthridine and the tear gas dibenz[b,f][1,4]oxazepine (CR) as extremely potent activators of the human transient receptor potential ankyrin 1 (TRPA1) channel.
Gijsen HJ; Berthelot D; Zaja M; Brône B; Geuens I; Mercken M
J Med Chem; 2010 Oct; 53(19):7011-20. PubMed ID: 20806939
[TBL] [Abstract][Full Text] [Related]
20. TRPA1 modulators in preclinical development.
Viana F; Ferrer-Montiel A
Expert Opin Ther Pat; 2009 Dec; 19(12):1787-99. PubMed ID: 19939193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
